IMmune-mediated Adverse drug Reactions In African HIV endemic setting (IMARI-SA study)
The following grant was awarded by, is supported by, is administered by or is in partnership with the Fogarty International Center at the U.S. National Institutes of Health (NIH).
Funding Fogarty Program
Emerging Global Leader
Project Information in NIH RePORTER
IMmune-mediated Adverse drug Reactions In African HIV endemic setting (IMARI-SA study)
Principal Institution
University of Cape Town Lung Institute
Principal Investigator(s) (PI)
Peter, Jonathan
Project Contact Information
Email: jonny.peter@uct.ac.za
Year(s) Awarded
2018-2023
Country
South Africa
Project Description
Immune-mediated adverse drug reactions (IM-ADRs) are a major obstacle to treatment success in both TB and HIV and a cause of tremendous morbidity, management complexity and economic burden. IM-ADRs are 100-fold more common in persons with HIV/AIDs, and over-represented in Africa; however, the immune pathogenesis is poorly understood, especially in non-European and HIV-infected populations. This study will fill significant gaps in our understanding of IM-ADR, for drugs used to treat HIV and TB in African populations.
Related World Regions / Countries
Related Global Health Research Topics